3 FTSE Shares You Should Have Bought Last Week: Mulberry Group PLC, Hargreaves Lansdown plc and Hikma Pharmaceuticals Plc

The FTSE 100 (INDEXFTSE:UKX) got trounced this week by Mulberry Group PLC (LON: MUL), Hargreaves Lansdown plc (LON: HL) and Hikma Pharmaceuticals Plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Last week the FTSE 100 (FTSEINDICES: ^FTSE) closed down 185 points, or 2.75%, on the start of the week. Investors were spooked ahead of the referendum in Crimea and economic data indicated a slowdown in China.

If you kept your nerve and bought shares — a great business is still a great business, no matter what market sentiment is — then you might have picked up a bargain or two.

Here are some of the top risers:

Mulberry 

MulberryShares in Mulberry (LSE:  MUL) hiked 5% this week after the chief executive, Bruno Guillon, resigned after serving two years in the role. His tenure had not been successful.

Earlier this year Mulberry’s shares plunged 24% after announcing another profit warning. Guillon stated at the time that the company “continues to invest in the ongoing process of transforming Mulberry from a domestic to a global luxury brand.”

That was his failing. The result of this strategy was a steep hike in prices, that put off consumers. Mulberry has been rudderless for some time after the brand’s creative director, Emma Hill, resigned last summer in opposition to the new direction.

Mulberry’s previous success was based on designs that were expensive, but not out of reach, for many British shoppers. Even in 2009, during the recession, UK sales improved 40%.

Today? Nobody’s buying a Mulberry bag that costs upwards of £1,000. Instead, customers have defected to cheaper brands such as Coach and Michael Kors.

Godfrey Davis, the company’s chairman, will take over until a successor is found.

Hargreaves Lansdown

_ISA2Hargreaves Lansdown (LSE: HL) was a big beneficiary from George Osborne’s Budget announcement on Wednesday. The shares are up 11% since the beginning of the week.

The gains came at the expense of leading insurers, such as Aviva and Legal & General — which fell 11% and 7% respectively — after it was announced that pensioners will no longer require an annuity to remove money from their pension pot.

Hargreaves Lansdown, the UK’s largest investment platform, should receive an upswing in business as pensioners take their savings as a lump sum and invest money in the stock market.

A similarly favourable news snippet was the announcement that ISAs, which currently exist in two forms — cash and stocks — will be merged into a single “New ISA” with a higher annual savings limit of £15,000. Hargreaves sells ISAs, and again, will benefit here.

Hikma Pharmaceuticals

astrazenecaAnalysts were widely predicting Hikma Pharmaceuticals’ (LSE: HIK) final results would show a 90% earnings increase. The shares have been thriving on these expectations.

When the official figures were unveiled they smashed the forecasts, coming in at 111%, and the share price has increased 7% on last week.

Since the beginning of the year Hikma’s gains have more than tripled the leading blue-chip pharma companies GlaxoSmithKline and AstraZeneca combined. Being a smaller company, Hikma Pharmaceuticals is potentially a more attractive growth stock than its larger brethren.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Mark does not own shares in any company mentioned. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

British coins and bank notes scattered on a surface
Investing Articles

Can this UK stock really deliver a high 19% dividend yield?

Stocks with high dividend yields can play a big part in an investor's quest for passive income. Let's look behind…

Read more »

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Investing Articles

No savings at 30? Here’s how a Stocks & Shares ISA could help turn £1,000 per month into £1,000,000

A 6.5% average annual return is enough to turn £1,000 per month into £1m over 30 years. And a Stocks…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This dynamic UK stock has a 9.5% dividend yield and could be 43% undervalued

Does this UK stock have a rare combination of both dividend and growth potential? Let's examine a bit closer and…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

I’ve just bought this excellent S&P 500 stock for my ISA

Our writer thinks Salesforce (NYSE:CRM) could be a big S&P 500 winner as it doubles down on the artificial intelligence…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The FTSE 250 can offer some growth bargains. But here are 3 risks to watch out for!

Christopher Ruane explains a trio of factors he considers when sifting through the FTSE 250 looking for potential bargain shares…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

2 defensive shares for investors to consider for passive income in 2025

Ken Hall takes a look at two reliable dividend payers in defensive sectors that could help build a long-term passive…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Growth Shares

Now could be the opportunity for me to snap up overlooked FTSE shares

Jon Smith explains why the recent record FTSE levels could push investors towards looking at more undervalued stocks within the…

Read more »

piggy bank, searching with binoculars
Dividend Shares

A 7.6% yield? Here’s the dividend forecast for a reliable FTSE 250 trust

Jon Smith runs through a potential income gem with a dividend forecast that indicates the dividend per share is heading…

Read more »